Alkermes plc EVP and Chief Legal Officer David Joseph Gaffin reported an open-market sale of 2,034 Ordinary Shares of Alkermes on June 4, 2026 at an average price of $43.05 per share. After this transaction, he directly holds 229,524 Ordinary Shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on November 19, 2025, indicating it was scheduled in advance rather than timed opportunistically.
Alkermes plc submitted a Form 144 notice concerning proposed sales of Common Stock on 06/04/2026 for shares traded on NASDAQ. The filing lists vested restricted stock unit awards of 506 (03/03/2015) and 1,528 (03/01/2018) shares and records four prior sales in the past three months: 59,575.86, 60,531.84, 70,315.38, and 67,528.80.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 5,000 Ordinary Shares at $19.34 per share and sold 9,000 Ordinary Shares in an open-market transaction at a weighted average price of $41.6715 per share.
Both the option exercise and the share sale were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025, meaning they were pre-arranged. The sale price reflects multiple trades between $41.37 and $42.19. After these transactions, Hopkinson directly holds 77,389 Ordinary Shares.
Craig Hopkinson reported dispositions of Alkermes plc ordinary shares via Form 144. The filing lists three sales of 9,000 shares each on 03/02/2026, 04/01/2026, and 05/01/2026, with proceeds shown as $267,485.14, $319,604.00, and $300,559.55 respectively. The record also shows recent issuer-related activity including a broker-assisted cashless exercise of 5,000 shares on 06/01/2026 and a vesting of a performance share award of 4,000 shares on 02/05/2026.
Alkermes plc VP of Finance (Interim PAO) Samuel Joseph Parisi reported an exercise-and-sell transaction in company stock. On May 29, 2026, he exercised employee stock options to acquire a total of 16,217 Ordinary Shares at exercise prices of $19.34 and $20.03 per share. He then sold 16,217 Ordinary Shares in open-market transactions at a weighted average price of $42.3634 per share, with individual sale prices ranging from $42.245 to $42.50. After these transactions, he directly held 7,717 Ordinary Shares of Alkermes.
Alkermes plc director Christopher I. Wright reported several compensation-related equity transactions. On May 21, 2026, 6,142 restricted stock units were exercised into ordinary shares, with 1,475 shares withheld at $36.95 per share to cover tax obligations rather than sold on the market. Wright also received new awards on May 20, 2026: 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price, expiring on May 20, 2036. Following these transactions, he holds 27,680 ordinary shares directly. Footnotes clarify each restricted stock unit converts into one ordinary share and that the new awards vest in full around the next annual general meeting.
Alkermes plc. director Wilson Frank Anders reported several routine equity compensation moves. On May 21, 2026, he exercised 6,142 Restricted Stock Units, receiving the same number of ordinary shares, and had 1,475 ordinary shares withheld to cover tax obligations at $36.95 per share. Following these transactions, he directly held 35,751 ordinary shares.
On May 20, 2026, he received a new grant of 5,409 Restricted Stock Units, each representing a contingent right to one ordinary share, and a Non Qualified Stock Option for 11,538 ordinary shares with an exercise price of $36.98 per share, expiring on May 20, 2036. The filing describes these events as grants, vesting, and tax-withholding rather than open-market buying or selling.
Alkermes plc. director Nancy Lynn Snyderman, MD reported routine equity compensation activity and related tax withholding. On May 21, 2026, she exercised a previously granted restricted stock unit award for 6,142 ordinary shares, and 1,475 shares were disposed of to cover tax obligations, not as an open-market sale.
On May 20, 2026, she received new equity awards: 5,409 restricted stock units, each representing the right to one ordinary share, and a non qualified stock option for 11,538 ordinary shares with a $36.98 exercise price expiring in 2036. A separate entry shows 20,783 ordinary shares held indirectly through the Nancy Lynn Snyderman Revocable Trust, where she is sole trustee and sole beneficiary.
Alkermes plc director Brian P. McKeon reported multiple equity transactions involving ordinary shares and equity awards. He exercised restricted stock units covering 6,142 ordinary shares, with 1,475 shares withheld at $36.95 per share to satisfy tax obligations, leaving 38,536 ordinary shares held directly after the tax-withholding disposition.
He also received a new restricted stock unit award for 5,409 units and a non-qualified stock option for 11,538 shares with a $36.98 exercise price, both granted at no cash cost and each RSU representing a contingent right to one ordinary share. In addition, 10,000 ordinary shares are held indirectly by The Brian P. McKeon Revocable Trust, of which he and his wife are trustees.
Alkermes plc director Nancy Lurker reported routine equity compensation and related share activity. On May 20, 2026, she received a grant of 5,409 Restricted Stock Units and a Non Qualified Stock Option for 11,538 ordinary shares with an exercise price of $36.98 per share, expiring on May 20, 2036.
On May 21, 2026, 6,142 Restricted Stock Units were exercised into ordinary shares, and 1,475 shares were disposed of at $36.95 per share to satisfy tax obligations. Following these transactions, she directly held 18,222 ordinary shares.